Aurinia Announces Public Offering of Common Shares
March 13 2017 - 3:01PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia”
or the “Company”), a clinical stage biopharmaceutical company
focused on the global immunology market, today announced that it
has commenced a registered underwritten public offering of its
common shares (the “Offering”).
Leerink Partners LLC and Cantor Fitzgerald & Co.
(collectively, the “Underwriters”) are acting as joint book-running
managers for the Offering. The Company will grant the Underwriters
an option exercisable, in whole or in part, in the sole discretion
of the Underwriters, to purchase additional shares, for a period of
up to 30 days.
The offering is subject to market conditions, as well as NASDAQ
and TSX approvals, and there can be no assurance as to whether or
when the offering may be completed, or the actual size or terms of
the offering. For the purposes of the TSX approval, the Company
intends to rely on the exemption set forth in Section 602.1 of the
TSX Company Manual, which provides that the TSX will not apply its
standards to certain transactions involving eligible inter-listed
issuers on a recognized exchange, such as NASDAQ. The Company
intends to use the net proceeds of the Offering for research and
development activities, including Phase 3 clinical trial activities
for lupus nephritis, and working capital purposes.
The Offering is being made pursuant to a U.S. registration
statement on Form F-10, declared effective by the United States
Securities and Exchange Commission (the “SEC”) on November 5, 2015
(the “Registration Statement”), and the Company’s existing Canadian
short form base shelf prospectus (the “Base Shelf Prospectus”)
dated October 16, 2015. The prospectus supplements relating to the
Offering (together with the Base Shelf Prospectus and the
Registration Statement, the “Offering Documents”) will be filed
with the securities commissions in the provinces of British
Columbia, Alberta and Ontario in Canada, and with the SEC in the
United States. The Offering Documents will contain important
detailed information about the securities being offered. Before you
invest, you should read the Offering Documents and the other
documents the Company has filed for more complete information about
the Company and the Offering. Copies of the Offering Documents will
be available for free by visiting the Company’s profiles on the
SEDAR website maintained by the Canadian Securities Administrators
at www.sedar.com or the SEC’s website at www.sec.gov, as
applicable. Alternatively, copies of the prospectus supplement will
be available upon request by contacting Leerink Partners LLC;
Attention: Syndicate Department; One Federal Street; 37th Floor;
Boston, MA, 02110, or by phone at 1-800-808-7525, ext. 6142, or by
email at syndicate@leerink.com or Cantor Fitzgerald & Co.,
Attn: Capital Markets, 499 Park Ave., 5th Floor, New York, New York
10022, or by telephone at 212-829-7122, or by e-mail at
prospectus@cantor.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities, nor will there be any
sale of the securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such
jurisdiction.
ABOUT AURINIAAurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering
from serious diseases with a high unmet medical need. The Company
is currently developing voclosporin, an investigational drug, for
the treatment of lupus nephritis (LN). The Company is headquartered
in Victoria, British Columbia and focuses its development efforts
globally.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170313006325/en/
Aurinia Pharmaceuticals Inc.Investors:Celia EconomidesHead of IR
&
Communicationsceconomides@auriniapharma.comorMedia:Christopher
Hippolyte, 917-826-2664Christopher.hippolyte@inventivhealth.com